gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
gptkbp:available_on
|
generic version
|
gptkbp:brand
|
gptkb:imatinib_mesylate
|
gptkbp:chemical_formula
|
C22 H26 N6 O2 S
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
gptkbp:clinical_use
|
targeted therapy
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to imatinib
|
gptkbp:developed_by
|
gptkb:Novartis
|
gptkbp:discovery
|
gptkb:Dr._Nicholas_Lydon
|
gptkbp:discovery_year
|
gptkb:1996
|
gptkbp:dosage_form
|
oral tablet
|
gptkbp:effective_date
|
gptkb:2001
|
gptkbp:fdaapproval_status
|
approved
|
gptkbp:fdaapproval_type
|
New Drug Application
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gleevec
|
gptkbp:indication
|
gptkb:Philadelphia_chromosome-positive_leukemia
gptkb:dermatofibrosarcoma_protuberans
gptkb:myelodysplastic_syndromes
|
gptkbp:ingredients
|
gptkb:imatinib
|
gptkbp:interacts_with
|
gptkb:warfarin
certain antibiotics
certain antifungals
certain anticonvulsants
|
gptkbp:invention
|
gptkb:Novartis_AG
gptkb:2015
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Gleevec
gptkb:Canada
gptkb:United_States
|
gptkbp:mechanism_of_action
|
tyrosine kinase inhibitor
|
gptkbp:name
|
Essential Medicines List
|
gptkbp:previous_name
|
gptkb:imatinib
|
gptkbp:research_areas
|
molecular biology
oncology
hematology
pharmacology
|
gptkbp:route_of_administration
|
oral
|
gptkbp:safety
|
Category D
|
gptkbp:shelf_life
|
3 years
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
edema
|
gptkbp:storage
|
room temperature
|
gptkbp:trade
|
gptkb:Gleevec
|
gptkbp:used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
|
gptkbp:weight
|
493.6 g/mol
|
gptkbp:bfsParent
|
gptkb:Novartis
|
gptkbp:bfsLayer
|
4
|